TransMedics Group, Inc. (NASDAQ:TMDX) Receives $102.00 Average Target Price from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $102.00.

A number of equities analysts have recently issued reports on the stock. Piper Sandler assumed coverage on shares of TransMedics Group in a report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price target for the company. Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Oppenheimer increased their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,047,155.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,047,155.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The disclosure for this sale can be found here. In the last three months, insiders sold 117,078 shares of company stock worth $9,972,971. 6.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Venturi Wealth Management LLC purchased a new stake in shares of TransMedics Group during the first quarter worth about $30,000. Global Retirement Partners LLC purchased a new stake in shares of TransMedics Group during the third quarter worth about $38,000. Cutler Group LLC CA grew its holdings in shares of TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after buying an additional 600 shares in the last quarter. RiverPark Advisors LLC purchased a new stake in shares of TransMedics Group during the third quarter worth about $60,000. Finally, First Horizon Advisors Inc. grew its holdings in shares of TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after buying an additional 222 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Down 1.9 %

Shares of TransMedics Group stock opened at $88.88 on Thursday. The company has a market cap of $2.91 billion, a P/E ratio of -115.43 and a beta of 1.99. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. TransMedics Group has a one year low of $36.42 and a one year high of $99.63. The firm has a fifty day moving average of $82.94 and a two-hundred day moving average of $74.12.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group’s quarterly revenue was up 158.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.21) EPS. On average, analysts forecast that TransMedics Group will post -0.14 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.